The U.S. drugmaker did not disclose the reason behind the rejection, but said it was reviewing the FDA's response. » Read More
By: Evelyn Cheng
Drugmakers may soon face renewed pressure on high prices, now that Republicans have pulled their American Health Care Act, Citi says. » Read More
By: Meg Tirrell
The track record in drug development for Alzheimer's disease has been terrible: a success rate of less than 1 percent. » Read More
By: Jayne O'Donnell, Frank Gluck and Darla Carter
A rural and urban divide, along with racial differences, were also evident in a new report on drug overdoses, USA Today reports. » Read More
The treatment demonstrated significant improvement in lung function in a pair of late-stage trials
Stelios Papadopoulos, Biogen chairman, speaks to CNBC's Meg Tirrell about the future of drug pricing, tax reform and M&A under President Trump.
Almost 200,000 people have fatally overdosed on opioids in the past 15 years, with more than 30,000 people dying in 2015 alone.
A billionaire doctor who's been spotted with Trump promoted a questionable therapy on his Twitter, STAT News reports.
Europe's medicines regulator has recommended the suspension of generic drug approvals due to "unreliable" tests conducted by an Indian firm.
TipRanks identified the corporate insiders with the best-performing track records and the stocks they are buying.
Judge Edgardo Ramos in Manhattan dismissed Express Scripts' claim that Anthem breached an implied covenant of good faith and fair dealing.
John Rountree, partner at Novasecta, discusses how the pharmaceutical industry is reacting to U.S. President Donald Trump's delayed health care bill.
The Israeli pharmaceutical company is denying reports that it planned to fire up to 11 percent of its workforce.
CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug.
After an experimental painkiller designed to be safer to use has outperformed in testing, Nektar Therapeutics is exploring next steps.
A new study finds that poison control centers across the U.S. field 32 calls a day from families with a child who has been exposed to opioids.
Alex Gorsky, CEO of Johnson & Johnson, talks about the opportunities available in the Chinese healthcare space and US-China relations.
Alex Gorsky, CEO of Johnson & Johnson, says it's important that the number of those uninsured stays at a low figure.
Johnson & Johnson CEO Alex Gorsky spoke with CNBC about health care from the China Development Forum in Beijing.
CNBC's Meg Tirrell reports on what the 2017 budget blueprint could mean for the health care industry.
Get the best of CNBC in your inbox